Answers are grounded in this paper and cite their sources.
Despite the benefits of protease inhibitor (PI)-based HIV treatment, issues of tolerability, dosing frequency, pill count and long-term metabolic complications necessitate evaluation of alternate treatment strategies. The weight of evidence demonstrates that a switch from a PI-based regimen to one containing nevirapine can be accomplished safely while maintaining virological suppression. There is no immunological cost. There is probably an overall benefit in terms of the metabolic milieu.
No takes yet. Share an insight, caveat, or question.
C L Cooper (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: